| Market Capitalization (Millions $) |
988 |
| Shares
Outstanding (Millions) |
89 |
| Employees |
21 |
| Revenues (TTM) (Millions $) |
60 |
| Net Income (TTM) (Millions $) |
-181 |
| Cash Flow (TTM) (Millions $) |
-48 |
| Capital Exp. (TTM) (Millions $) |
5 |
Business Description
Verve Therapeutics Inc is a biotechnology company that focuses on developing gene-editing therapies for the treatment of cardiovascular diseases like high cholesterol and heart disease. The company was founded in 2019 and is headquartered in Cambridge, Massachusetts.
Verve has massive potential to revolutionize the field of cardiovascular medicine by developing gene-editing therapies to treat patients with high cholesterol and heart disease, which are two of the leading causes of death worldwide. Verve utilizes groundbreaking technology called CRISPR/Cas9 that allows them to edit genes and thereby eliminate the root cause of these diseases. By targeting the genes responsible for high cholesterol and cardiac disorders, the company aims to create long-lasting and potentially curative therapies to help millions of people globally.
The company is led by a team of renowned scientists and business leaders who have significant experience in the biotechnology industry. Specifically, co-founders Dr. Sekar Kathiresan, Andrew Bellinger, Dr. Kiran Musunuru, and Dr. Robert Plenge are all highly regarded in their respective fields, and collectively have a vast amount of biotech and pharmaceutical experience. They are supported by a team of accomplished researchers, executives, and advisors who are committed to advancing the company's mission.
In addition to its groundbreaking technology platform, Verve has also established partnerships with leading academic institutions, including the Broad Institute of MIT and Harvard, to help accelerate its research and development efforts. The company has also secured significant funding from top investors in the biotechnology industry, including GV (formerly Google Ventures), Biomatics Capital, and Casdin Capital, to name a few.
Despite being a relatively young company, Verve Therapeutics Inc has already achieved significant milestones and has gained considerable attention from the media and industry experts. The company's innovative approach to treating cardiovascular diseases has the potential to transform the healthcare industry, save countless lives, and generate substantial returns for its investors.
Company Address: 201 Brookline Avenue Boston 2215 MA
Company Phone Number: 603-0070 Stock Exchange / Ticker: NASDAQ VERV
|
0.05%